在生物界的漫长进化历程中，逆转录酶的发现改变了人们对遗传信息传递方式的认识。在较多真核生物中，端粒酶逆转录酶通过逆转录将端粒DNA加至真核细胞染色体末端，填补DNA复制损失的端粒，以保护基因组的完整性。在逆转录病毒（RNA病毒）中，逆转录酶将病毒RN ...

CRF: Circulating recombinant form; NNRTI: Non-nucleoside reverse-transcriptase inhibitor; NRTI: Nucleos(t)ide analog reverse-transcriptase inhibitor. Eight nucleos(t)ide analog reverse ...

Sequence variations in human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) and protease, the molecular targets of anti-retroviral drug therapy, are prime examples of genes in which ...

The risk for VTE was reduced among Military Health Systems beneficiaries who were vaccinated vs unvaccinated against COVID-19.

The four main classes, which most people are treated with, target one of three viral proteins which control HIV’s lifecycle: reverse transcriptase, integrase and protease. Historically, most people ...

Generally, the dual NRTI backbone treatment of combination with a non-NRTI (NNRTI) or protease inhibitor (PI) should comprise a cytidine analogue (lamivudine, emtricitabine) and a thymidine ...

In South Korea, this candidate has already proceeded to phase I and II trials. It works by regulating the production of human ...

Specific subtypes and transmission clusters for HIV could require targeted interventions to control spread of HIV that is ...

10月30日晚间，艾迪药业(688488.SH)发布2024年三季报。前三季度，公司实现营业收入约2.99亿元，第三季度实现营收1.18亿元，同比大增87.54%。其中，公司HIV新药销售增长喜人，有力支撑了公司的业绩增长。 报告显示，公司HIV新药第三季度销售收入约5248.59万元，同比增长284.23%，前三季度实现销售收入约1.34亿元，同比增长188.51%。 公司艾滋病领域创新药复邦德 ...

More than 46,000 of them had been prescribed a form of HIV-suppressing medications known as reverse transcriptase (RT) inhibitors. Among this subgroup, Alzheimer's diagnoses occurred in about 2.5 ...

其中在HIV新药方面，2024年前三季度公司HIV新药合计实现销售收入13,411.98万元，同比增长188.51%。而得益于报告期内公司扎实推进“医学引领、市场拉动、销售落地”的营销思路落地的缘故，公司第三季度HIV新药合计实现销售收入5,248.59万元，同比增长284.23%。